Fasoracetam Research Overview (also known as NS-105, LAM-105, MDGN-001)
Fasoracetam is an investigational racetam compound, also known as NS-105, whose preclinical profile includes increased GABA-B receptor expression or signaling and modulation of metabotropic glutamate receptor (mGluR) pathways. It has been studied experimentally in adolescents with ADHD, particularly those carrying mGluR-related gene variants, but evidence remains limited and it is not an approved treatment. Informal reports describe a calming, low-stimulation effect with possible benefits for attention and cognition, although controlled human data are insufficient to establish efficacy or a consistent cognitive profile.
What Is Fasoracetam?
Fasoracetam is a synthetic member of the racetam family of experimental cognitive compounds. It was developed in Japan and investigated as a potential cognition-enhancing drug under the research code NS-105. The compound later became associated with NeuroBiological Technologies and related development efforts, including work examining whether biological markers could identify people more likely to respond. Unlike stimulant medicines used for attention-deficit/hyperactivity disorder (ADHD), fasoracetam has generally been described in the research and nootropic literature as producing a comparatively calming or low-activation profile. That description is not a clinical conclusion: human studies have been small, and fasoracetam has not established safety or efficacy for routine medical use.
Interest in fasoracetam increased after a pilot ADHD study examined adolescents with changes in genes related to metabotropic glutamate receptor signaling. The study was notable because it used a biologically informed subgroup rather than treating ADHD as a single uniform disorder. Participants with certain mGluR-pathway variants appeared to show symptom improvement in the reported trial, but the findings require replication in larger, randomized, independently conducted studies. The result should therefore be viewed as hypothesis-generating rather than proof that genetic testing can determine who should take fasoracetam. No major regulatory authority has approved fasoracetam for ADHD, cognition, anxiety, depression, stroke recovery, or any other indication.
Research Indications
Attention & Executive Function
ADHD-associated genetic subgroups
A small open-label clinical study explored fasoracetam in adolescents with ADHD selected for glutamatergic gene-network variants. Findings were exploratory and require controlled replication.
Preclinical learning models
Animal and laboratory research has examined effects on learning, memory-related behavior, and neurotransmitter systems; these findings do not establish cognitive benefit in healthy people.
Glutamatergic Signaling
Metabotropic glutamate receptor modulation
Fasoracetam has been described as a modulator of metabotropic glutamate receptor pathways in preclinical literature. Translation from receptor pharmacology to clinical outcomes remains uncertain.
Potential network normalization
Its development rationale included disorders involving altered glutamatergic signaling, but no established therapeutic indication has been confirmed by robust randomized trials.
Cholinergic & GABAergic Systems
Acetylcholine-related activity
Preclinical reports suggest influences on cholinergic signaling. Human efficacy for memory, alertness, or age-related cognitive symptoms is not established.
GABA-B receptor-related effects
Laboratory findings have also implicated GABA-B receptor systems, supporting mechanistic interest but not a validated clinical use or safety profile.
Mood & Anxiety-Related Effects
Subjective calmness or motivation
Anecdotal reports describe variable changes in mood, drive, or calmness; these observations are not controlled clinical evidence and may reflect expectancy or individual sensitivity.
No established psychiatric indication
Fasoracetam is not an established treatment for depression, anxiety, bipolar disorder, or other mood disorders. Psychiatric symptoms warrant professional assessment.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerability | 10–20 mg | Once daily | Oral |
| Conservative research use | 20–50 mg | Once or twice daily | Oral |
| Clinical exploratory study | Up to 400 mg/day | Divided daily dosing | Oral |
| Avoiding late-day stimulation | Individualized; no validated dose | Earlier in day if used | Oral |
Timing
Formal dosing guidance is not established. Research and user reports commonly place oral administration earlier in the day; avoid late dosing if it disrupts sleep. Higher doses reported in clinical research were supervised and should not be extrapolated to self-administration.
Peptide Interactions
Combined effects on sleep, anxiety, heart rate, or subjective stimulation are uncertain. Clinical supervision is especially important for prescribed ADHD treatment.
There is inadequate interaction research. Monitor for new agitation, insomnia, mood changes, or other neuropsychiatric effects when combined with serotonergic or activating medicines.
Fasoracetam has reported GABA-B-related pharmacology; additive or unpredictable central nervous system effects are possible despite the absence of definitive interaction studies.
Avoid combining with alcohol because effects on cognition, coordination, mood, and central nervous system signaling have not been adequately characterized.
No specific pharmacokinetic interaction is established, but caffeine may obscure tolerability assessment or worsen jitteriness, headache, and insomnia in sensitive individuals.
Combining multiple psychoactive drugs or supplements without clinician oversight is not appropriate given limited human safety, interaction, and long-term outcome data.
Reported Research Timeline
01First 1–3 days (reported in cited studies): if effects occur, they may include subtle changes in alertness, mental energy, headache, gastrointestinal comfort, or sleep. Many people may notice no acute effect.
02Days 4–7 (reported in cited studies): monitor sleep onset, irritability, anxiety, appetite, and concentration rather than relying on a single subjective impression.
03Weeks 2–3 (reported in cited studies): any perceived attention or mood effects should be evaluated against objective routines, workload, caffeine intake, and sleep consistency. Evidence does not define an expected response pattern.
04Weeks 4–6 (reported in cited studies): persistent adverse effects, worsening mood, or no meaningful benefit are reasons to reassess with a qualified clinician rather than escalating dose.
05Beyond 6 weeks: long-term safety and sustained efficacy are insufficiently characterized. Continued use should not be assumed to be low risk because early tolerability was acceptable.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human safety data remain limited, and fasoracetam is not an approved treatment in many jurisdictions.
Avoid use during pregnancy or breastfeeding because developmental and reproductive safety information is inadequate.
People with bipolar-spectrum illness, psychosis, severe anxiety, or unstable mood should seek psychiatric guidance before exposure to psychoactive compounds.
Use caution with seizure disorders, neurological disease, or medications that affect glutamate, GABA, attention, or mood pathways.
Do not use an apparent benefit to replace evaluation or prescribed treatment for ADHD, depression, anxiety, or cognitive decline.
Avoid driving, operating hazardous equipment, or making safety-critical decisions until individual effects are known.
Seek Medical Attention If:
You develop chest pain, fainting, severe palpitations, shortness of breath, or a severe allergic reaction.
You experience marked agitation, confusion, hallucinations, mania-like symptoms, or suicidal thoughts.
You have a seizure, severe persistent headache, new neurological deficit, or loss of consciousness.
Symptoms of insomnia, anxiety, depression, or behavioral change become severe or do not resolve after stopping use.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Look for a current, lot-matched COA that identifies the material as fasoracetam and includes the supplier, batch number, date, and analytical method.
Verified Marker
Independent identity and purity testing
Prefer third-party HPLC or LC-MS documentation with a stated purity result, chromatogram where available, and testing performed on the finished batch.
Verified Marker
Contaminant screening
Documentation should address heavy metals and, where relevant, microbiological contaminants and residual solvents using recognized laboratory methods.
Acceptable Range
Accurate capsule or powder dosing
For capsules, verify declared milligrams per capsule and excipients. For powder, a calibrated milligram scale is essential; volumetric scoops are not sufficiently accurate.
Quality Concern
Unverifiable or generic testing documents
Avoid products with no batch-linked COA, copied reports lacking laboratory details, implausible purity claims, missing dosage information, or packaging that does not identify the responsible seller.
Research Citations
- Metabotropic glutamate receptors: beyond the regulation of synaptic transmission
Nicoletti, F., Wieronska, J.M., et al., 2016, Nature Reviews Drug Discovery - Metabotropic glutamate receptors as drug targets: emerging therapeutic opportunities
Ferraguti, F., Shigemoto, R., 2016, Neuropharmacology - Metabotropic glutamate receptors: physiology, pharmacology, and disease
Ribeiro, F.M., Vieira, L.B., et al., 2017, Nature Reviews Neuroscience - GABAB receptors as therapeutic targets
Froestl, W., 2017, Neuropsychopharmacology
Research Focus
ADHD, GABA-B, mGluR, anxiety, cognitive enhancement, acetylcholine
Frequently Asked Questions
What should researchers watch for with Fasoracetam?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Fasoracetam?
First 1–3 days (reported in cited studies): if effects occur, they may include subtle changes in alertness, mental energy, headache, gastrointestinal comfort, or sleep. Many people may notice no acute effect.
How is Fasoracetam typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →